Survey Finds 10 Million Americans Microdosed Psychedelics In 2025

An estimated 10 million Americans microdosed on psychedelics in 2025, according to a report citing the 2025 RAND Psychedelics Survey.

The survey, conducted in September, covered a nationally representative sample of 10,122 adults aged 18+ and living in the U.S.

The survey asked respondents who reported using psilocybin, LSD, or MDMA in the past year how many days they had used the substances, and how many days they had microdosed the substances, defining microdosing as “taking a small fraction of a regular dose (a subperceptual dose) that is much lower than you would take to ‘trip’ or hallucinate on these substances.” According to the report, 69% of adults who reported using psilocybin said they had microdosed at least one day in the last year. Psilocybin was the most popular psychedelic to microdose, compared to MDMA (65%) and LSD (59%).

“There is an emerging discussion about the effects of microdosing on creativity, well-being, and mental health, but until now little was known about how common it is. Our findings suggest that for those who use psychedelics, taking small doses is a big deal.” — Michelle Priest, RAND researcher and the report’s lead author, in a press release

According to the survey, the five psychedelics used most commonly by Americans in 2025 were psilocybin (11 million adults), MDMA (4.7 million), Amanita muscaria mushrooms (3.5 million), ketamine (3.3 million), and LSD (3 million).